Merck KGaA and Pfizer Terminates P-III JAVELIN Ovarian PARP 100 Study for Advanced Ovarian Cancer

 Merck KGaA and Pfizer Terminates P-III JAVELIN Ovarian PARP 100 Study for Advanced Ovarian Cancer

Merck KGaA Collaborates with GenScript for the Expansion of Cell and Gene Therapies in China

Shots:

  • The termination is based on P-III JAVELIN Ovarian PARP 100 study (B9991030) results assessing Bavencio (avelumab) + CT followed by avelumab + Talzenna (talazoparib) vs PBO in 9,000 patients with locally advanced or metastatic ovarian cancer
  • The termination is due to its third failure with unmet degree of benefit observed with avelumab in ovarian cancer responding to its discontinuation & approval of AstraZeneca’s PARP Lynparza in ovarian cancer
  • Bavencio (avelumab) is a mAb targeting PD-L1 protein while blocking PD-L1 interaction with PD-1 receptor. Talzenna (talazoparib) is a PARP inhibitor used in treatment of BRCA mutated breast cancer. In November 2014, Merck & Pfizer collaborated to co-develop & co-commercialize avelumab

Click here to read full press release/ article | Ref: Merck KGaA | Image: Wikimedia Commons

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post